Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
暂无分享,去创建一个
[1] P. Wen,et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma , 2012, Leukemia.
[2] O. Baser,et al. Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry , 2012, Current medical research and opinion.
[3] A. Bosi,et al. The Role of Bortezomib, Thalidomide and Lenalidomide in the Management of Multiple Myeloma , 2011, PharmacoEconomics.
[4] L. Tanoue. Cancer Statistics, 2011: The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths , 2012 .
[5] W. Feng,et al. Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs , 2012, PharmacoEconomics.
[6] J. Dürig,et al. Potent Anti-Leukemic Activity of a Novel Cdk9 Inhibitor in Preclinical CLL Mouse Models , 2011 .
[7] Ruth E. Brown,et al. Cost-Effectiveness of Lenalidomide in Multiple Myeloma Patients with 1 Prior Therapy in England and Wales, , 2011 .
[8] P. Fayers,et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. , 2011, Blood.
[9] D. Woulfe. PKD is for dense granule secretion. , 2011, Blood.
[10] A. Jemal,et al. Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.
[11] J. Snowden,et al. Guidelines for supportive care in multiple myeloma 2011 , 2011, British journal of haematology.
[12] M. Dimopoulos,et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. , 2011, Blood.
[13] H. Goldschmidt,et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. , 2011, Cancer treatment reviews.
[14] T. Szucs,et al. Cost differences among treatment options for patients with refractory myeloma previously treated with high-dose chemotherapy and autologous stem-cell transplantation: An analysis from the U.S. and Swiss perspectives. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] D. Koleva,et al. Healthcare costs of multiple myeloma: an Italian study. , 2011, European journal of cancer care.
[16] M. Beksac,et al. Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. , 2011, The oncologist.
[17] E. Zamagni,et al. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. , 2011, Seminars in thrombosis and hemostasis.
[18] A. Palumbo,et al. Shifts in the Therapeutic Paradigm for Patients Newly Diagnosed with Multiple Myeloma: Maintenance Therapy and Overall Survival , 2011, Clinical Cancer Research.
[19] F. Fagnani,et al. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi‐centre retrospective cohort study , 2011, Journal of clinical pharmacy and therapeutics.
[20] J. Möller,et al. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib , 2011, Journal of medical economics.
[21] M. Amonkar,et al. Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population , 2011, Journal of medical economics.
[22] M. Baccarani,et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study , 2010, The Lancet.
[23] M. Boccadoro,et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Hornberger,et al. The cost‐effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective , 2010, European journal of haematology.
[25] B. Barlogie,et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Miguel,et al. A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib , 2010 .
[27] D. Esseltine,et al. The Cost-Effectiveness of Bortezomib Plus Melphalan and Prednisone Versus Lenalidomide Plus Melphalan and Prednisone with Continuous Lenalidomide Maintenance Treatment for the Initial Treatment of Multiple Myeloma In the United States , 2010 .
[28] M. Kersten,et al. HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM) , 2010 .
[29] M. Mohty,et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Ji,et al. Repression of Id2 expression by Gfi-1 is required for B-cell and myeloid development. , 2010, Blood.
[31] I. Higginson,et al. Cost–effectiveness of lenalidomide in multiple myeloma , 2010, Expert review of pharmacoeconomics & outcomes research.
[32] Xiaodong Yang,et al. Mir-886-3p Contributes to the Regulation of the hematopoietic microenvironment by down-Regulating SDF-1α (CXCL12). , 2009 .
[33] D. Esseltine,et al. The Cost-Effectiveness of Bortezomib for the Initial Treatment of Multiple Myeloma in the United States. , 2009 .
[34] J. Vose,et al. NCCN clinical practice guidelines in oncology: multiple myeloma. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[35] R. Kyle,et al. Treatment of multiple myeloma: a comprehensive review. , 2009, Clinical lymphoma & myeloma.
[36] M. Dimopoulos,et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG) , 2009, Leukemia.
[37] H. Brenner,et al. Expected long-term survival of patients diagnosed with multiple myeloma in 2006–2010 , 2008, Haematologica.
[38] M. Dimopoulos,et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma , 2009, Leukemia.
[39] Wei Chen,et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation , 2009, Leukemia.
[40] Bin Jiang,et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.
[41] Lisa C. Smith,et al. Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board. , 2008, Clinical journal of oncology nursing.
[42] D. Dingli,et al. Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.
[43] H. Brenner,et al. Recent major improvement in long-term survival of younger patients with multiple myeloma. , 2008, Blood.
[44] D. Esseltine,et al. A Budget Impact Model Comparing Resource Utilization of Four Approved Therapies for Multiple Myeloma (MM) in the US. , 2007 .
[45] Anthony Boral,et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. , 2007, Blood.
[46] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003 , 2006 .
[47] A. Basu,et al. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. , 2005, Biostatistics.
[48] Terry M Therneau,et al. Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.
[49] J. T. Wulu,et al. Regression analysis of count data , 2002 .
[50] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.